Donepezil Hydrochloride + Placebo
ApprovedCompleted 0 watching 0 views this week🔥 Hot
85
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Memory Loss
Conditions
Memory Loss
Trial Timeline
Dec 1, 2003 → Mar 1, 2007
NCT ID
NCT00293176About Donepezil Hydrochloride + Placebo
Donepezil Hydrochloride + Placebo is a approved stage product being developed by Eisai for Memory Loss. The current trial status is completed. This product is registered under clinical trial identifier NCT00293176. Target conditions include Memory Loss.
Hype Score Breakdown
Clinical
30
Activity
20
Company
10
Novelty
10
Community
12
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00688376 | Phase 3 | Completed |
| NCT00293176 | Approved | Completed |
Competing Products
8 competing products in Memory Loss
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Roflumilast + Roflumilast placebo + Donepezil + Donepezil placebo + Scopolamine | AstraZeneca | Phase 1 | 33 |
| Aricept + IFN-alpha2A | Pfizer | Phase 2 | 51 |
| Tolterodine ER + Oxybutynin ER | Pfizer | Approved | 84 |
| Levetiracetam, Keppra | UCB | Approved | 82 |
| Piracetam | UCB | Pre-clinical | 20 |
| EGb 761® (Tanakan®) | Ipsen | Approved | 82 |
| LX6171 High Dose + LX6171 Low Dose + Placebo | Lexicon Pharmaceuticals | Phase 2 | 47 |
| Fruitflow-II + resVida | Brain Biotech | Pre-clinical | 15 |